You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
Agreement incorporates TYMLOS ® and abaloparatide-TD Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S.
BOSTON , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company’s board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by the
Continued growth in net new patients for the month of November 2020 Company is on-track for record quarter in net revenue for TYMLOS-SC Research Agreement reached with MGH in October 2020 Hired Head of Clinical Development for the abaloparatide molecule WALTHAM, Mass. , Dec.
TYMLOS ® U.S. net sales of $50 million with 8% year-over-year growth; Total Revenues of $78 million Q3 commercial pivot to focus on high risk fracture segment is gaining traction: Net New U.S. Patients increased by 7+% in September 2020 vs. previous 3-month moving average and 10 +% in October vs.
Completed e nrollment in 3 p ivotal c linical t rials; multiple data read outs in Q4 2021 Released meaningful abaloparatide histomorphometry data at recent ASBMR meeting Completed two business development transactions with existing oncology asset s Repositioned commercial effort to focus on high
WALTHAM, Mass. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020 . The Company will host a conference call and live audio webcast at 8:30 a.m.
Business development step enables molecule to move forward Program progression will be at no financial risk to Radius Reinforces Radius ’ focus on execution of core business WALTHAM, Mass. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the
Organizational Change with in Finance Function Creates Capital, Strategy & Transac tions Group WALTHAM, Mass. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jose (Pepe) Carmona will be stepping down as Chief Financial
Includes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan WALTHAM, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American